First-in-Human Phase I Study of GSK2126458, an Oral Pan-Class I Phosphatidylinositol-3-Kinase Inhibitor, in Patients with Advanced Solid Tumor Malignancies
Author(s) -
Pamela N. Münster,
Rahul Aggarwal,
David S. Hong,
Jan H.M. Schellens,
Ruud Van Der Noll,
Jennifer M. Specht,
Petronella O. Witteveen,
Theresa L. Werner,
E. Claire Dees,
Emily K. Bergsland,
Neeraj Agarwal,
Joseph F. Kleha,
Michael Durante,
Laurel M. Adams,
Deborah A. Smith,
Thomas A. Lampkin,
Shan R. Morris,
Razelle Kurzrock
Publication year - 2016
Publication title -
carolina digital repository (university of north carolina at chapel hill)
Language(s) - English
DOI - 10.17615/22bk-cn61
Subject(s) - phosphatidylinositol , kinase , class (philosophy) , phase (matter) , medicine , cancer research , oncology , biology , chemistry , computer science , genetics , artificial intelligence , organic chemistry
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom